Search research articles
Contact Us
Filters
Showing results (501-510 of 535) with videos related to
Page
of 54
Sort By:
The New England Journal of Medicine
|
August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization
Ruben Niesvizky, Tomer M Mark, Maureen Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
ESMO Open
|
November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
L Frehner, S Schär, S Hayoz, et al.
Cell Reports
|
March 2, 2022
IKKα Promotes Intestinal Tumorigenesis by Limiting Recruitment of M1-like Polarized Myeloid Cells
Serkan I Göktuna, Ozge Canli, Julia Bollrath, et al.
Cell Reports
|
June 3, 2014
IKKα promotes intestinal tumorigenesis by limiting recruitment of M1-like polarized myeloid cells
Serkan I Göktuna, Ozge Canli, Julia Bollrath, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
June 14, 2020
Resident mesenchymal vascular progenitors modulate adaptive angiogenesis and pulmonary remodeling via regulation of canonical Wnt signaling
Megan E Summers, Bradley W Richmond, Swapna Menon, et al.
ESMO Open
|
April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
D König, S Schär, D Vuong, et al.
ESMO Open
|
April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D König, S Schär, D Vuong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
Myo Htut, Anita D'Souza, Amrita Krishnan, et al.
Page
of 54
Search research articles
Search
Showing results (501-510 of 535) with videos related to
Sort By:
Page
of 54
The New England Journal of Medicine
|
August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization
Ruben Niesvizky, Tomer M Mark, Maureen Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
ESMO Open
|
November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
L Frehner, S Schär, S Hayoz, et al.
Cell Reports
|
March 2, 2022
IKKα Promotes Intestinal Tumorigenesis by Limiting Recruitment of M1-like Polarized Myeloid Cells
Serkan I Göktuna, Ozge Canli, Julia Bollrath, et al.
Cell Reports
|
June 3, 2014
IKKα promotes intestinal tumorigenesis by limiting recruitment of M1-like polarized myeloid cells
Serkan I Göktuna, Ozge Canli, Julia Bollrath, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
June 14, 2020
Resident mesenchymal vascular progenitors modulate adaptive angiogenesis and pulmonary remodeling via regulation of canonical Wnt signaling
Megan E Summers, Bradley W Richmond, Swapna Menon, et al.
ESMO Open
|
April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
D König, S Schär, D Vuong, et al.
ESMO Open
|
April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D König, S Schär, D Vuong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
Myo Htut, Anita D'Souza, Amrita Krishnan, et al.
Page
of 54